Top 5 Best-Selling Cancer Drugs

Page 5 of 5

1. Keytruda 

Total Sales: 38.1 billion  

Keytruda (pembrolizumab) is a leading cancer immunotherapy drug, generating substantial revenue with over $6.3 billion in sales during Q3 2023, a 17% increase from the previous year. The drug has maintained strong growth, priced at $11,115.04 per dose every three weeks and $22,230.08 every six weeks. Keytruda’s versatility extends to various disease stages, including metastatic and earlier-stage indications like triple-negative breast cancer, along with approval for adjuvant treatment in non-small cell lung cancer and is also called the best selling drug in the world.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also take a peek at the 30 Best Cardiology Hospitals In the US and the 20 Countries With The Highest Life Expectancy in the World.

Page 5 of 5